Cross-Bridge versus Thin Filament Contributions to the Level and Rate of Force Development in Cardiac Muscle  by Regnier, M. et al.
Cross-Bridge versus Thin Filament Contributions to the Level
and Rate of Force Development in Cardiac Muscle
M. Regnier,* H. Martin,y R. J. Barsotti,y A. J. Rivera,* D. A. Martyn,* and E. Clemmens*
*Department of Bioengineering, University of Washington, Seattle, Washington 98195; and yDepartment of Pathology,
Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
ABSTRACT In striated muscle thin ﬁlament activation is initiated by Ca21 binding to troponin C and augmented by strong
myosin binding to actin (cross-bridge formation). Several lines of evidence have led us to hypothesize that thin ﬁlament
properties may limit the level and rate of force development in cardiac muscle at all levels of Ca21 activation. As a test of this
hypothesis we varied the cross-bridge contribution to thin ﬁlament activation by substituting 2 deoxy-ATP (dATP; a strong cross-
bridge augmenter) for ATP as the contractile substrate and compared steady-state force and stiffness, and the rate of force
redevelopment (ktr) in demembranated rat cardiac trabeculae as [Ca
21] was varied. We also tested whether thin ﬁlament
dynamics limits force development kinetics during maximal Ca21 activation by comparing the rate of force development (kCa)
after a step increase in [Ca21] with photorelease of Ca21 from NP-EGTA to maximal ktr, where Ca
21 binding to thin ﬁlaments
should be in (near) equilibrium during force redevelopment. dATP enhanced steady-state force and stiffness at all levels of
Ca21 activation. At similar submaximal levels of steady-state force there was no increase in ktr with dATP, but ktr was enhanced
at higher Ca21 concentrations, resulting in an extension (not elevation) of the ktr-force relationship. Interestingly, we found that
maximal ktr was faster than kCa, and that dATP increased both by a similar amount. Our data suggest the dynamics of Ca
21-
mediated thin ﬁlament activation limits the rate that force develops in rat cardiac muscle, even at saturating levels of Ca21.
INTRODUCTION
Striated muscle contraction results from cyclic interactions
between myosin and actin, which are regulated by the
troponin-tropomyosin complex of the thin ﬁlament. Ca21
binding to the thin ﬁlament regulatory protein troponin C
(TnC) initiates contraction (Gordon et al., 2000) and the level
of force developed is determined by the availability of myosin
binding sites on thin ﬁlaments, which is ultimately controlled
by the distribution of tropomyosin (Tm) between positions on
the surface of thin ﬁlaments that either block or uncover
binding sites on actin for myosin cross-bridge attachment.
Transduction of the Ca21 signal is through the troponin
complex, resulting in increased mobility of Tm over the
surface of actin and exposure of strong binding sites for
myosin. This shifts the thin ﬁlament from a ‘‘blocked’’ to
a ‘‘closed’’ state (McKillop and Geeves, 1993), thereby
allowing further myosin cross-bridge formation. Strong
cross-bridge binding is then thought to stabilize Tm in an
‘‘open’’ state and the thin ﬁlament is considered ‘‘activated.’’
In effect, the level of contractile activation appears to result
from a balance of the effects of Ca21 binding to TnC and
cross-bridges on Tm state. The growing amount of evidence
suggests that cross-bridge displacement of Tm into an
activating position may play a more prominent role in the
regulation of cardiac contraction (Fuchs and Smith, 2001).
Like force, the rate of force development is Ca21
dependent, but the mechanisms that determine the thin
ﬁlament activation dependence of force kinetics are less well
established. In demembranated skeletal muscle ﬁbers the
relationship between steady-state force and the rate that force
redevelops (ktr) after a release-restretch cycle is Ca
21
sensitive, being slow (1–2 s1 at 10–15C) at low levels of
force and increasing 10–15-fold as force rises to maximum at
high levels of Ca21 activation (Brenner, 1986, 1988). Based
on these and other ﬁndings it was suggested that Ca21
controls the rate-limiting process in force development rather
than simply controlling the level of cross-bridge recruitment
(Brenner, 1986, 1988). However, we and others have shown
that in skeletal muscle when the Ca21-activated force is high
the kinetics of actin-myosin interaction are likely limiting to
the rate of force development, whereas at submaximal force
the rate-limiting process may be the kinetics of thin ﬁlament
activation (Chase et al., 1994; Regnier et al., 1996, 1998;
Fitzsimmons et al., 2001a,b). This limiting process is greatest
at low levels of activation, as most of the increase in ktr comes
at Ca21 concentrations that produce.50%ofmaximal Ca21-
activated steady-state force.
Similar to reports for fast skeletal muscle, ktr is Ca
21
dependent in demembranated cardiac muscle. However, most
studies have reported smaller magnitude (one- to ﬁvefold)
change in ktr (compared with skeletal muscle) as the level of
Ca21 activation is varied (Wolff et al., 1995; Palmer and
Kentish, 1998; Patel et al., 2001), though one recent report
suggest a .8-fold change (Fitzsimons et al., 2001). These
studies mostly show that at similar temperatures ktr is similar
or faster in cardiac versus skeletal muscle at low Ca21
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concentrations, and slower at high levels of Ca21 activation.
This suggests the lower Ca21 dependence of ktr results from
different actin-myosin cycling kinetics (the main determinant
of maximal ktr in skeletal muscle) and/or the relative kinetics
of thin ﬁlament processes versus actin-myosin cycling
kinetics is different than in skeletal muscle (Hancock et al.,
1997). Coupled with evidence that thin ﬁlament activation
level is more dependent on strong cross-bridge binding in
cardiac (versus skeletal) muscle, it also suggests that Ca21
binding to Tnmay result in less complete activation of cardiac
thin ﬁlaments (Regnier et al., 2000b).
We have been studying the relative contribution of Ca21
binding to TnC and cross-bridge binding on both the level of
thin ﬁlament activation and the rate that force develops in
cardiac and skeletal muscle. A particularly successful
approach has been to alter cross-bridge binding and cycling
rates by using nucleotide analogs of ATP (NTPs) as the
substrate for contraction. We have shown that one of these
analogs, 2 deoxy-ATP (dATP), has an afﬁnity for skeletal
myosin similar to that of ATP and increases both solution
NTPase and unloaded shortening velocity of rabbit skeletal
and rat cardiac muscle (Regnier and Homsher, 1998; Regnier
et al., 1998, 2000b). Interestingly, dATP enhances both
maximal Ca21-activated steady-state force (Fmax) and ktr in
cardiac trabeculae from both untreated rats, containingmostly
a-MHC (fast cardiac myosin), and PTU-treated rats,
containing b-MHC (slow cardiac myosin) (Regnier et al.,
2000b). This contrasts with our ﬁndings in skeletal muscle
where dATP has no effect on Fmax, but increases maximal ktr
in rabbit psoas ﬁbers (fast skeletal myosin) and rat soleus
ﬁbers (slow skeletal myosin) (Regnier et al., 1998). These
results indicate that cross-bridge cycling rate per se cannot
explain these cardiac versus skeletal muscle differences, and
suggests that the properties of cardiac thin ﬁlament regulatory
proteins may limit cross-bridge cycling. Therefore we have
hypothesized that (compared to ATP) dATP augments the
level of thin ﬁlament activation and/or strong cross-bridge
binding at saturating Ca21 concentration in demembranated
cardiac muscle, resulting in an increase in Fmax and maximal
ktr over that attained with ATP as the contractile substrate.
This hypothesis is supported by our ﬁnding that dATP also
enhances both force and ktr at subsaturating levels of Ca
21
activation in skeletal muscle (Regnier et al., 1998).
In this study we hypothesized that the relatively low
activation dependence of ktr in cardiacmuscle (comparedwith
skeletal muscle) reﬂects a relative limitation of Ca21 binding
to TnC to activate thin ﬁlaments at all levels of Ca21.
Consequently, this would give cross-bridge binding a more
prominent role in the activation process. To test this
hypothesis we compared steady-state force and stiffness,
and ktr in rat cardiac trabeculae as Ca
21 concentration was
variedwith either 5mMATPor 5mMdATP as the contractile
substrate. In addition, we tested the hypothesis that thin
ﬁlament kinetics can limit the rate of force development
during maximal Ca21 activation. To do this we compared the
rate force develops after a step increase in Ca21 concentration
with photorelease of Ca21 from NP-EGTA (kCa) (Ellis-
Davies andKaplan, 1994) tomaximal ktr, where Ca
21 binding
to thin ﬁlaments should be in (near) equilibrium during force
development. We found that dATP enhanced steady-state
force and stiffness at all levels of Ca21 activation. We also
found that at similar submaximal levels of steady-state force
there was no increase in ktr with dATP, but dATP enhanced ktr
at higher Ca21 concentrations, resulting in an extension (not
elevation) of the curvilinear force-ktr relationship. Similar
results were obtained for rat trabeculae with either a-MHC or
b-MHC isoforms, indicating this effect was not due to the
absolute rate of cross-bridge cycling. Signiﬁcantly, we found
that ktr is faster than kCa with maximal Ca
21 activation, and
that both are increased a similar amount by dATP. This
ﬁnding suggests the kinetics and/or level of Ca21-mediated
thin ﬁlament activation may limit the rate that force develops
in rat cardiac muscle, even at saturating levels of Ca21. In
a subsequent article, (Adhikari et al., 2004), we show that this
property of cardiac thin ﬁlamentsmay at least partially explain
the greater sarcomere length-dependence of force found in
cardiac (versus skeletal) muscle. Preliminary reports of this
work have been published previously (Regnier et al., 2000a;
Martin et al., 2002).
METHODS
Male Sprague-Dawley rats (200–250 grams), either treated with propylthio-
uracil (PTU; 0.5% added to drinking water for 4–8 weeks) or untreated (as
age-matched animals) were euthanized with sodium pentabarbitol (50 mg/
kg). Hearts were excised and the interior wall of the right ventricle exposed
to relaxing solution (see below) containing glycerol (50% v/v) and Triton
X-100 (1%) overnight at 5C. Individual trabeculae were dissected and
stored at 5C for up to 4 days.
Solutions
Experimental solutions contained (in mM): 15 phosphocreatine, 15 EGTA,
at least 40 3-(N-morpholino)propanesulfonic acid (MOPS), 1 free Mg21,
135 Na1 1 K1, 1 dithiothreitol (DTT), 250 units ml1 creatine kinase (CK,
Sigma, St. Louis, MO), and either 5 ATP or 5 mM 2 deoxy-ATP (Sigma, St.
Louis, MO) at pH 7.0 and 156 1C. Ionic strength was 0.2 M. Afﬁnities of
dATP and ATP for Mg21 were assumed to be the same (Regnier and
Homsher, 1998). For activation solutions, the Ca21 level (expressed as
pCa ¼ log [Ca21]) was set by adjusting Ca(propionate)2.
Individual chemically demembranated (‘‘skinned’’) trabeculae were
wrapped in aluminum foil T-clips for attachment to a force transducer (either
Model 400A, 2.2 kHz-resonant frequency (Cambridge Technology, Water-
town, MA) or Model AE801, $5 kHz resonant frequency (SensoNor,
Horton, Norway)) and a servo-motor (model 300, Cambridge Technology,
Watertown, MA) tuned for a 300 ms-step response. For most experiments
trabecular sarcomere length (Ls) was measured with helium-neon laser
diffraction (Chase et al., 1993) and set to 2.25 mm at pCa 9.2. At this Ls
trabeculae lengths ranged from 1.2–2.3 mm and diameters averaged 140 6
16 mm, with no signiﬁcant difference between trabeculae from normal
versus PTU-treated rats. Stiffness was determined by small amplitude
(0.05% Ls) sinusoidal length oscillations (1 kHz). Steady-state isometric
force is reported as kN/M2 in Results, assuming circular geometry and the
rate of isometric tension redevelopment (ktr) was determined from the
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halftime of force recovery after a rapid release-restretch transient, as
previously described (Regnier et al., 1998). For comparisons, force and ktr
are reported normalized to measurements obtained during maximal Ca21
activation with ATP as the contractile substrate.
Comparisons of maximal ktr with the rate of force development (kCa) after
photorelease of Ca21 from NP-EGTA were made during the same activation
done in a separate set of experiments under identical conditions, except
temperature was 17C instead of 15C. kCa was measured as described in
Martin et al. (2004). Brieﬂy, after initial Ca21 activations in either ATP or
dATP, during which control measurements of ktr were performed at maximal
activation (ktr control), the preparation was transferred through a series of NTP
containing solutions to a ﬁnal photolysis solution containing 5 mM NTP,
2mMNP-EGTA, and;1.8 mM added calcium. The output from a frequency
doubled ruby laser producing ;150 mJ in a 50 ns pulse at a wavelength of
347 nm (Laser Applications, Winter Park, FL) was focused onto the trabecu-
lae. Incident energy was measured by deﬂecting 10% of the beam energy
onto a Scientech Energy Meter (365, Boulder, CO); ;2 s after peak force
was attained, ktr was measured (ktr photolysis) and the tissue relaxed. For these
experiments, all elicited transients were collected for subsequent analysis
but only those resulting in maximal activations within 5% of maximal
Ca21-activated force at pCa 4.0 (Fmax) have been included in the data.
Data analysis
Force-pCa and ktr-pCa relationships are ﬁt with the Hill equation:
F ¼ Fmax=ð11 10nHðpCa50pCaÞÞ: (1)
From each Hill ﬁt, the pCa at half-maximal force or ktr (pCa50) and the slope
(nH) are determined, and reported pCa50 and nH values represent the means
of the values from the individual ﬁts, 6 SE. The time course of force
development from ktr and kCa protocols was determined by exponential ﬁts
or from t1/2 values, as previously described in (Chase et al., 1994), both
yielding similar results. Summarized data are reported as mean 6 SE and




In chemically demembranated (skinned) trabeculae, sub-
stitution of 5 mM dATP for 5 mM ATP increased steady-
state force at all levels of Ca21 activation. The steady-state
force data for all the experiments is summarized in Fig. 1.
Trabeculae from untreated and PTU-treated rats were used to
determine if force enhancement by dATP depends on the
myosin isoforms present. Force values were normalized to
Fmax with ATP for each trabecula and the Ca
21-dependence
of force was characterized from ﬁtting the Hill equation to
the data (Eq. 1 in Methods) to obtain 1), the [Ca21] required
to elicit half of maximal Ca21-activated force (i.e., pCa50 or
Ca21 sensitivity); and 2), the slope (nH or Hill coefﬁcient)
of the steep portion of the force-pCa relationship. For
trabeculae from untreated rats Fmax was 20.0 6 4.2 kN/m
2
with ATP (n¼ 8) and was increased by 316 3% with dATP
(Fig. 1 a). In trabeculae from PTU-treated rats Fmax was 17.6
6 4.2 kN/m2 with ATP (n ¼ 10) and was increased by 396
4% with dATP (Fig. 1 b). These increases in Fmax with dATP
are similar to what we have previously reported (Regnier
et al., 2000b). dATP increased the Ca21-sensitivity of force
(pCa50) of trabeculae from both untreated and PTU-treated
rats, but had no signiﬁcant effect on nH. For trabeculae from
untreated rats, dATP increased the Ca21-sensitivity of force
(P , 0.05) by 0.13 pCa units from 5.41 6 0.01 (ATP) to
5.546 0.03 (dATP), whereas corresponding nH values were
5.46 0.6 (ATP) and 4.66 1.2 (dATP). For trabeculae from
PTU-treated rats, pCa50 with ATP was similar to untreated
rats, whereas the increase of Ca21 sensitivity of force with
dATP was greater than found for untreated rats, increasing
0.26 pCa units from 5.43 6 0.01 (ATP) to 5.69 6 0.03
(dATP). nH was unaffected by dATP in PTU treated
trabeculae (3.2 6 0.2 (ATP) vs. 3.5 6 0.6 (dATP)). The
Hill ﬁt parameters (pCa50 and nH) for the force-pCa relations
for trabeculae from untreated and PTU-treated rats included
in Table 1.
In a subgroup of trabeculae from PTU-treated rats, steady-
state stiffness wasmeasuredwith small amplitude oscillations
(see Methods). Linear regression analysis of the stiffness
versus force relationship (as Ca21 was varied) for activations
in ATP versus dATP demonstrated a proportional increase in
FIGURE 1 dATP (s) enhances the Ca21-sensitivity of steady-state force
in skinned trabeculae. Force was normalized to maximal force at pCa 4.5
with ATP (d) for trabeculae from normal (a) and PTU-treated (b) rats for
comparisons. Data are reported as the mean6 SE for each pCa. Data were ﬁt
to Eq. 1 (Methods) and values for pCa50 and nH are reported in the text of
Results. Fits for the data were r2 . 0.997.
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stiffness versus force for both nucleotides (Fig. 2). This
suggests the increased force with dATP at each pCa results
from enhanced strong cross-bridge binding.
Rate of force redevelopment (ktr)
Similar to the results with steady-state force, dATP enhanced
ktr at varying levels of Ca
21 activation. The force traces in
Fig. 3 show this enhancement for example trabeculae from
an untreated (Fig. 3 a) and a PTU-treated (Fig. 3 b) rat during
activations at pCa 5.5 and pCa 4.0. In both of these examples
trabeculae dATP elevated steady-state force at pCa 5.5 and
pCa 4.0 by similar amounts versus ATP, and at pCa 5.5, ktr
was approximately doubled whereas maximal ktr (pCa 4.0)
was increased by 27 6 5% (untreated) and 47 6 4% (PTU-
treated). Fig. 4 summarizes ktr measurements at varying
levels of activating Ca21, normalized to pCa 4.0 and ATP.
At 15C maximal ktr with ATP was 10.6 6 0.8 s1 (n ¼ 8)
for trabecula from untreated rats and 3.0 6 0.2 s1 (n ¼ 10)
for trabeculae from PTU-treated rats. The data show that
dATP increased ktr at higher levels of Ca
21 activation, but
had little or no effect on ktr at the lowest levels of activation.
Although the starting level of force after restretch of muscle
ﬁbers varied somewhat between preparations and between
measurements with ATP versus dATP within the same
preparation, there was no indication these variable starting-
force levels affected the magnitude differences in ktr between
ATP and dATP. Hill ﬁts to the data indicate an increase in
the Ca21 sensitivity (pCa50) of ktr with dATP. In trabeculae
from untreated rats (Fig. 4 a) pCa50 was increased by 0.10
units (P , 0.05) from 5.28 6 0.01 (ATP) to 5.38 6 0.01
(dATP). This increase in the Ca21 sensitivity of ktr was
similar to the increase seen for steady-state force (Fig. 1 a)
and stiffness (Fig. 2). For trabeculae from PTU-treated rats
TABLE 1 Comparison of Hill ﬁt parameters for force-pCa and ktr-pCa relations in untreated (control) and PTU-treated rats
NTP Fmax (normalized) pCa50 (force) nH (force) Max. ktr (normalized) pCa50 (ktr)
Untreated ATP (8) 1.0 5.41 6 0.01 5.4 6 0.6 1 5.28 6 0.01
dATP (8) 1.31 6 0.03 5.54 6 0.03 4.6 6 1.2 1.27 6 0.05 5.38 6 0.01
PTU ATP (10) 1.0 5.43 6 0.01 3.2 6 0.2 1 5.42 6 0.01
dATP (10) 1.39 6 0.04 5.69 6 0.03 3.5 6 0.6 1.47 6 0.04 5.47 6 0.01
The number of trabeculae used for each NTP condition is given in parentheses. Fmax and maximal ktr values are normalized to force obtained with 5 mM ATP
at pCa 4.5.
FIGURE 2 Relationship between steady-state force and trabeculae
stiffness with varying [Ca21] for 3 trabeculae from PTU-treated rats. Force
and stiffness values are normalized to the level measured at pCa 4.0 with
ATP as the contractile substrate. Linear regression ﬁts to the ATP (n) and
dATP (h) data yielded identical slopes of 0.96 with r2 values .0.97. The
values for dATP .1.0 demonstrate that trabeculae stiffness is elevated
proportionally with force over values for ATP, suggesting an increase in the
number of strongly bound, force-producing cross-bridges at high levels of
Ca21 activation.
FIGURE 3 Example force records comparing ktr with ATP versus dATP
at pCa 5.5 and 4.0 for trabeculae from an untreated (a) and a PTU-treated (b)
rat. The pCa and rate of force redevelopment (ktr) for each trace are given
next to the respective force records. These examples demonstrate elevation
of both steady-state force and ktr at submaximal and maximal levels of Ca
21
activation.
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(Fig. 4 b), the pCa50 of ktr was increased by 0.05 units (P ,
0.05) from 5.42 6 0.01 (ATP) to 5.47 6 0.01 (dATP), an
increase not as profound as that seen for steady-state force
(Fig. 1 b). These data are included in Table 1 for comparison
to the corresponding steady-state force values.
The leftward shift observed for both the force versus pCa
(Fig. 1) and ktr versus pCa (Fig. 4) relationships suggest that
increases in ktr with dATP may have resulted from an
increased number of cross-bridges available to participate in
the force-generating process. To test this idea, the ktr data in
Fig. 4 were replotted as ktr versus force (both normalized to
pCa 4.0 with ATP) at each level of Ca21 in activation solu-
tions (Fig. 5). This replotting of the data clearly demonstrates
that ktr was similar for dATP during Ca
21-activated contrac-
tions producing similar levels of steady-state force and was
elevated by dATP only at activation levels resulting in greater
steady-state force than that obtained with ATP during
maximal Ca21 activation. When coupled with the stiffness
data, which rises proportionally with force (Fig. 2), it also
suggests that ktr with dATP is increased because of a greater
recruitment of force generating cross-bridges at each level of
activating Ca21, including during maximal Ca21 activation.
Rate of force development (kCa)
To investigate how Ca21 activation processes might limit the
rate of force development in cardiac muscle we compared the
rate of force development under conditions where the [Ca21]
is kept constant (ktr) versus when activation is initiated by
a step increase in [Ca21] by laser photolysis of NP-EGTA
(kCa). Fig. 6 (upper panel) shows an example of the protocol
used for these comparisons. This trabecula was placed in
a control activation solution (pCa 4.5, 5 mM ATP) to
determine Fmax andmaximal ktr (ﬁrst arrow), then was placed
in relaxing solution (pCa 8.0). Next the trabecula was
transferred into the NP-EGTA activation solution to allow
the caged-Ca21 to diffuse into the contractile lattice (2–3
min.). At this point the trabecula was activated by photolysis
of the NP-EGTA (second arrow) and steady-state force
developed, ;2 s later a ktr measurement was made (third
arrow) and the trabecula was relaxed. In several preparations
the ktr measurement was repeated in control activation
FIGURE 4 TheCa21 dependence of ktr withATP (d) versus dATP (s) for
trabeculae from untreated (a) and PTU-treated (b) rats. Measurements with
ATP and dATP are made in the same preparations and values are normalized
tomaximal ktr at pCa 4.0withATP. Values are mean6 SE. Data were ﬁt with
Eq. 1 (Methods) to demonstrate an increase in the Ca21 sensitivity (pCa50) of
ktr, as well as maximal ktr, with dATP in both (a) and (b).
FIGURE 5 The relationship between steady-state force and ktr as pCa is
varied with ATP (n) versus dATP (h) for trabeculae from untreated (a) and
PTU-treated (b) rats. Values are mean 6 SE. In both a and b, ktr is not
different for ATP versus dATP at similar levels of steady-state force, but
dATP extends the curve beyond maximal values of force and ktr for ATP
(demonstrated by dotted lines) at high levels of Ca21 activation.
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solution (not shown) to conﬁrm that photolysis produced
maximal Ca21-activation conditions. The kCa / ktr pro-
cedure was then repeated for activations with dATP as the
contractile substrate (right side of Fig. 6, upper panel ). The
order of NTP testing was varied between preparations.
Comparisons of ktr and kCa were made only for maximal
Ca21 activation and then only if the photolysis of NP-EGTA
produced Ca21 activation within 5% of the force level in
control activations. For this example trabecula it is obvious
this is the case and that Fmax was increased by dATP in both
control and NP-EGTA activations.
Fig. 6, a–d, shows the ktr and kCa measurements for ATP at
greater resolution and demonstrates two consistent ﬁndings:
1), steady-state force and ktr after activation by photolysis of
NP-EGTA was similar to control activations; and 2), kCa
was slower than ktr. Fig. 7 shows higher time resolution
examples of kCa and the subsequent ktr force traces comparing
activations with ATP versus dATP, demonstrating that both
measurements are faster when dATP is the substrate for
contraction. The data for all experiments is summarized in
Table 2. The ktr averaged 75% faster than kCa for ATP and
65% faster for dATP, suggesting that the relative difference
FIGURE 6 Procedure for sequential
measurements of kCa and ktr. (Upper
panel) An example triton skinned rat
trabeculae was transferred through a se-
ries of solutions containing 5 mM ATP
(left) or dATP (right) with the indicated
pCa (17C). Where NP-EGTA is in-
dicated the trabecula was transferred to
a solution containing 2 mM NP-EGTA
with 1.8 mM added Ca21, then acti-
vated by a pulse of laser light (arrow,
hn). Measurements of ktr were made at
pCa 4.5 in control solution (ktr control)
and during maximal activation induced
by photolysis of NP-EGTA (ktr photolysis).
kCa was determined from the time
course of the transient after NP-EGTA
photolysis. (Lower panel) Rapid time
base recordings from upper panel. (a)
ktr photolysis for ATP determined imme-
diately after activation by photolysis of
NP-EGTA. (b) kCa induced by photo-
lysis of NP-EGTA with ATP. (c)
ktr control for ATP. Rates are determined
from the t1/2 of the respective transients.
(d) Force records from a and b super-
imposed to show relative rates.
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between the twomeasurements is independent of cross-bridge
cycling rates. The data also show that dATP increased ktr by
50% and kCa by 60% over measurements with ATP,
suggesting faster cross-bridge cycling (dATP) enhances both
rates by a similar mechanism.
DISCUSSION
There are three major ﬁndings from this study: 1), altering
cross-bridge cycling by substitution of dATP for ATP as the
contractile substrate increases the Ca21 sensitivity of steady-
state force (Fig. 1) and ktr (Fig. 4) in rat cardiac muscle at
15C, independent of myosin isoform; 2), both maximal
Ca21-activated steady-state force and the rate of force
development (ktr, kCa) can be signiﬁcantly increased by
increased cross-bridge binding and/or cycling rate (Fig. 5);
and 3), the maximal rate that force develops by a step increase
in Ca21 (kCa) is signiﬁcantly slower than the maximal rate of
force redevelopment (ktr) during activations with saturating
levels of Ca21. The maximal steady-state force and ktr data
agree with previous work in cardiac muscle where we
demonstrated that dATP elevates maximal Ca21 activated
force, ktr, unloaded shortening velocity and ﬁlament sliding
velocity in vitro motility assays (Regnier et al., 2000b). These
studies provide information about how altering cross-bridge
cycling inﬂuences cross-bridge binding and thin ﬁlament
activation at submaximal levels of Ca21 in cardiac muscle.
The results also allow us to compare results in cardiac muscle
with previouswork in fast and slow skeletal muscle, wherewe
have extensively studied the effects of cross-bridge binding
and cycling rates versus thin ﬁlament dynamics on the Ca21
activation dependence of steady-state force and force de-
velopment kinetics (Regnier et al., 1996, 1998, 1999,
2000a,b). Those studies provided strong evidence that thin
ﬁlament dynamics are limiting to the level and rate of force
development in skeletal muscle during submaximal Ca21
activation.
The existing structural sequences and conservation in-
formation for myosin heavy chains offer no explanation about
how dATP might increase Fmax in cardiac muscle, but not in
skeletal muscle (Regnier et al., 2000b). Indeed the increase in
Fmax with dATP may be peculiar to mammalian cardiac
muscle in general, as we have also found similar results in
chemically demembranated trabeculae from mouse and dog
heart (unpublished observations). In previous studies we
suggested that dATP might increase the number of force-
generating cross-bridges during submaximal Ca21 activation
in skeletal muscle (Regnier et al., 1998) and during maximal
Ca21 activation in cardiac muscle (Regnier et al., 2000b) by
increasing one or more transition rates associated with cross-
bridge attachment and force generation while increasing the
rate of cross-bridge detachment to a lesser extent. In this
article, we now propose this enhanced cross-bridge attach-
ment leads to increased activation, which is apparent at
submaximal Ca21 in both muscle types and in maximal force
in cardiac muscle.
Steady-state force
Proportional increases in steady-state force and stiffness were
found at all levels of Ca21 activation with dATP. This
apparent increase of thin ﬁlament activation could result from
recruitment of strongly bound force-generating cross-bridges,
from an increase in force per cross-bridge, or both. Since
dATP increases cross-bridge cycling rate, it suggests the
cross-bridge detachment rate (gapp) is increased,which further
implies the rate of strong cross-bridge attachment ( fapp) must
increase to a greater extent to provide a higher level of steady-
state force and stiffness (Regnier et al., 2000b). This effect of
dATP appears to be partially or completely independent of
the overall cross-bridge cycling rate, as there were increases
in both maximal force and Ca21 sensitivity of force for
trabeculae from untreated versus PTU-treated rats (Fig. 1;
Table 1). This suggests the effects of dATP are largely
independent of myosin kinetics (Figs. 3 and 4), implying that
enhanced strong cross-bridge binding is the important
contribution of dATP to increased activation. Whatever the
detailed mechanism of force enhancement by dATP, the net
result is an apparent elevation of thin ﬁlament activation at all
levels of Ca21 in cardiac muscle with either a- or b-MHC.
Interestingly, dATP increased the Ca21 sensitivity of force
(pCa50) for trabeculae with b-MHC twice as much as for
trabeculae with a-MHC (0.26 vs. 0.13 pCa units, respec-
tively; Fig. 1 and Table 1). This suggests enhanced cross-
bridge binding and/or cycling rate may improve activation in
cardiac muscle with slowmyosin. Our steady-state force-pCa
results (Fig. 1) contrast with those reported by Metzger et al.
(1999) in their study of myocytes from untreated versus PTU-
treated rats. Although we report no difference in the Ca21
sensitivity of force (pCa50) for trabeculae from untreated
versus PTU-treated rats, they observed a decrease in pCa50 by
0.17 units with no change in the slope (Metzger et al., 1999). It
is unclear why our results differ, but the focus and novel
discovery of our study is that increased cross-bridge binding
(with dATP) increases pCa50 of force for both untreated and
PTU-treated trabeculae without changing the apparent
cooperativity (nH) of the force-pCa relationship (Fig. 1).
In cardiac muscle changes in cross-bridge binding have
been shown to increase Ca21 binding to troponinC (Hofmann
and Fuchs, 1987; Wang and Fuchs, 1994; Martyn and
TABLE 2 Comparison of kCa and ktr in the same maximal Ca
21
activation with ATP versus dATP as the contractile substrate
ATP dATP dATP/ATP
kCa 4.3 6 0.7 (8) 6.9 6 0.4 (10) 1.61
ktr 7.6 6 0.6 11.4 6 1.4 1.49
The number of trabeculae used for each NTP condition is given in
parentheses. For most trabeculae, kCa and ktr measurements were made for
both ATP and dATP.
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Gordon, 2001). Our experiments do not allow us to determine
if enhanced Ca21 sensitivity of force with dATP is correlated
with increased Ca21 binding to troponin C or via Ca21-
independent increases in strong cross-bridge binding (or
both). The increased force at saturating [Ca21], however, is
most likely explained by increased cross-bridge binding alone
because of proportional increases in trabeculae stiffness. To
determine if force enhancement by dATP directly results in
a shifting of thin ﬁlament toward the ‘‘on’’ state will require
a more direct measurement of the state of tropomyosin on thin
ﬁlaments.
Rate of force development (ktr, kCa)
In this study the Ca21 sensitivity of ktr was increased with
dATP (Fig. 4; Table 1), similar to steady-state force. When ktr
was plotted versus the steady-state force produced at varying
[Ca21], it was apparent that ktr was similar at force and
stiffness levels common to both substrates. However, with
dATP both ktr and force rose substantially above maximal
levels for ATP for trabeculae from both untreated (Fig. 5 a)
and PTU-treated (Fig. 5 b) rats, indicating the effect was
independent of cardiac myosin isoforms (Regnier et al.,
2000b). Changes in the force-ktr relationship at high levels of
Ca21 with dATP could result from greater activation of thin
ﬁlaments by cross-bridges, as suggested by the increased
stiffness (Fig. 2). Evidence for elevation of the rate force
develops during submaximal Ca21 activation by enhanced
cross-bridge binding was provided by Fitzsimons et al.
(2001), who found that NEM S-1 binding to thin ﬁlaments at
submaximal forces raised ktr to levels measured during
maximal Ca21 activations. Since NEM S-1 cross-bridges are
strong binding and slowly dissociating, they suggested that
thin ﬁlaments with bound NEM S-1 were at a much higher
activation level than in the absence of NEM S-1 at the same
level of submaximal Ca21, thus allowing a faster rate of force
development. An additional effect of dATP may be directly
attributed to a faster rate of cross-bridge cycling with dATP
since maximal ktr is the sum of fapp 1 gapp, both of which
could be increased by dATP (Regnier et al., 2000b). How-
ever, the similar effect of dATP on ktr-force relations (Fig. 5;
Table 1) for trabeculae from untreated (mostly a-MHC) and
PTU-treated (b-MHC) rats indicates that cross-bridge cycling
rate cannot be the only factor limiting the level and rate of
force development in cardiac muscle. If ktr at submaximal
levels of activation is limited by the intrinsic acto-myosin
NTPase rate of cross-bridges, we should have observed an
elevation of ktr at all levels of force. In contrast, Fig. 5 shows
similar values of ktr for ATP and dATP at the same level of
force and stiffness, imply that a noncross-bridge cycling
mechanism is limiting the rate that force can develop. An
alternative interpretation of our results would be that the
amount of force generated per cross-bridge is enhanced with
dATP (compared with ATP). However, our previous ob-
servation that maximal Ca21-activated force is not elevated
by dATP in either fast or slow soleus skeletal muscle ﬁbers
argues against this. Slow skeletal ﬁbers contain the same
myosin isoform (b-MHC) present in trabeculae from PTU-
treated rats, indicating dATP-induced elevation of force does
not result from an increased level of force per cross-bridge.
This suggests that the elevation of force and ktr by dATP result
from cross-bridge dependent enhancement of thin ﬁlament
activation.
In cardiac muscle the relatively low Ca21-activation
dependence of ktr (a two- to ﬁvefold change compared with
a 10–15-fold change for skeletal muscle) could result from an
intrinsically lower acto-myosin ATPase activity at maximal
activation or a relative limitation of the level of thin ﬁlament
activation, even at saturating [Ca21]. The last possibility is
supported by the observations that 1), cardiac TnC (cTnC) has
a single regulatory Ca21-binding site (Johnson et al., 1980)
compared with the two regulatory Ca21-binding site for fast
skeletal muscle; 2), cTnC undergoes less and slower con-
formational change upon Ca21-binding than skeletal TnC
(Sia et al., 1997; Hazard et al., 1998); 3), the Ca21 induced
conformational change associated with TnI interaction is
slow for cardiac TnC (perhaps as low as 4–6 s1) (Dong et al.,
1996, 1997); and 4), when cardiac TnC is fully substituted
for endogenous TnC in skeletal ﬁbers maximum force is
signiﬁcantly lower (Chase et al., 1994; Morris et al., 2001).
An additional consideration is that the signal transmission of
Ca21 binding to TnC to tropomyosin could be slow relative to
cross-bridge cycling rates, especially at low Ca21 concen-
trations. If the level or rate of thin ﬁlament activation is limited
in cardiac muscle, interventions that elevate thin ﬁlament
activation might be expected to enhance bothmaximum force
and ktr, as we observe with dATP. We have previously
demonstrated that thin ﬁlament activation dynamics are
rate limiting to force development at low levels of Ca21 in
skeletal ﬁbers (Chase et al., 1994; Regnier et al., 1998). We
now suggest this mechanism may also apply to cardiac
muscle.
This hypothesis is further supported by comparisons of ktr
and kCa during the same activation of trabeculae at pCa 4.5.
For both ATP and dATP kCa was consistently only about half
as fast as ktr (Table 2, Figs. 6 and 7), indicating the dynamics
of thin ﬁlament activation by Ca21 limit the rate of force
development. However, because force develops from differ-
ent levels during ktr and kCameasurements, differences in time
courses of force rise could be inﬂuenced by the distribution of
compliance between cross-bridges and noncross-bridge
components (Huxley et al., 1994; Luo et al., 1994; Higuchi
et al., 1995; Martyn et al., 2002). Comparison of the force
traces in Fig. 7 indicates that the ktr force redevelops from
a nonzero value, whereas it rises from relaxed levels after
the Ca21 transient. As a result, in ktr measurements the
compliance of noncross-bridge structures would be high
relative to cross-bridge compliance at the beginning of force
development, resulting in an apparent slowing of force
kinetics (Luo et al., 1994;Martyn et al., 2002) and thus would
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underestimate the difference between ktr and kCa. In com-
parison, during kCa measurements noncross-bridge compli-
ance would be lowest at the beginning of force rise, thus the
initial rate of force development would be faster, slowing as
cross-bridge compliance decreases with increasing force.
However, there was no indication of an initial rapid rise of
force that approached ktr during kCa measurements. Thus
differences in distribution of compliance between cross-
bridge and noncross-bridge components do not explain the
different time course of ktr and kCa.
If cross-bridge cycling kinetics were limiting the rate of
force development, we would expect kCa and ktr to be similar.
The thin ﬁlament activation state should be in near
equilibrium during tension redevelopment with the ktr
protocol. Changes in myoplasmic [Ca21] during tension
transients (Vandenboom et al., 1998; Wang and Kerrick,
2002) or Ca21 binding when force is inhibited in cardiac
muscle (Wang and Fuchs, 1994; Martyn and Gordon, 2001)
indicate that some Ca21 dissociates from thin ﬁlaments
during the release-restretch transients of ktr measurements.
However, this amount is likely to be a small fraction of Ca21
bound to troponin C at pCa 4.5 (Martyn and Gordon, 2001).
Furthermore, any thin ﬁlament deactivation during the release
phase of the release-restretch transient would lead to a slower
value of maximal ktr, and thus underestimate differences
between ktr and kCa. In contrast, force development during the
kCa measurement begins with near zero levels of Ca
21 bound
to thin ﬁlaments. Thus our observation that kCa is always
slower than ktr supports a hypothesis that thin ﬁlament
activation byCa21 is rate limiting for force development even
at saturating [Ca21]. Previously Palmer and Kentish (1998)
reported no difference between kact (reported here as kCa) and
ktr in rat and guinea pig trabeculae at 22C. However these
measurements were not obtained during the same activation
and may have been from separate trabeculae. Additionally,
their kact values in rat trabeculae varied almost fourfold with
some activations producing more force than the control
activations, and maximum ktr varied by more than twofold.
This suggests some of their measurements may have been
made in submaximally activating conditions. The argument
that thin ﬁlament regulatory protein dynamics limit the rate
that force develops in cardiac muscle is further supported by
the observation that both rates were elevated;60% by dATP,
whereas kCa remained slower than ktr (Table 1). Thus, even
though cross-bridge cycling kinetics can be increased by
dATP, the kinetics of thin ﬁlament activation by Ca21 may
limit the rate force develops in rat cardiac muscle. If so,
mechanisms that enhance cross-bridge binding at a given
submaximal level of intracellular Ca21, such as phosphory-
lation of myosin-binding protein C could be important in
increasing the power output of the heart during sympathetic
stimulation. This mechanism would not be available to
skeletal muscle, where Ca21 binding to TnC appears to be
much more successful in fully activating thin ﬁlaments and
where contraction usually results from action potential trains
that allow muscles to contract at the upper end of the force-
pCa relationship.
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